D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA), on Monday, announced it has entered into an exclusive global license agreement with AnaptysBio Inc. (ANAB) for the development and commercialization ...

Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab.

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to rec ...